Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival

Annals of Surgical Oncology

Volumn 21, Issue 5, 2014, Pages 1530-1537

  Rose, J Bart ^a   Rocha, Flavio G ^a   Alseidi, Adnan ^a   Biehl, Thomas ^a   Moonka, Ravi ^a   Ryan, John A ^a   Lin, Bruce ^a   Picozzi, Vincent ^a   Helton, Scott ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BILIARY STENT; BLOOD TRANSFUSION; BORDERLINE RESECTABLE PANCREATIC CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CHEMORADIOTHERAPY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREAS RESECTION; PERINEURAL INVASION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE RADIOTHERAPY; RETROSPECTIVE STUDY; SURGICAL MORTALITY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR INVASION; UNSPECIFIED SIDE EFFECT; VEIN SURGERY; ADENOCARCINOMA; ADJUVANT THERAPY; CANCER STAGING; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; POSTOPERATIVE PERIOD; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84898851128     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3486-z     Document Type: Article

References (45)

1. Siegel R. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007;14:118-27. (Pubitemid 44954278)
3. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007;110:738-44. (Pubitemid 47257648)
4. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 2010;304:1073-81.
5. Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer. 2012;118:2674-81.
6. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA. 2013;310:1473-81.
7. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227-34. (Pubitemid 47435592)
8. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035-46. (Pubitemid 44337962)
9. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727-33.
10. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.
11. Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: A meta-analysis of prospective studies. Ann Surg Oncol. 2012;19:1644-62.
12. Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: A meta-analysis. World J Surg. 2012;36:884-91.
13. Morganti AG, Massaccesi M, La Torre G, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010;17:194-205.
14. Pendurthi TK, Hoffman JP, Ross E, Johnson DE, Eisenberg BL. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg. 1998;64:686-92. (Pubitemid 28294698)
15. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5:121-30. (Pubitemid 33652049)
16. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001;8:123-32. (Pubitemid 32199408)
17. Cheng T-Y, Sheth K, White RR, et al. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol. 2006;13:66-74. (Pubitemid 43117647)
18. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15:928-37. (Pubitemid 27106274)
19. Hoffman JP. Status of neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin N Am. 2010;19:411-8.
20. Crane CH, Varadhachary G, Wolff RA, Pisters PWT, Evans DB. The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:365-82.
21. Regine W, Winter K. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma. JAMA. 2008;299:1019-26. (Pubitemid 351347058)
22. Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg. 2011;35:1580-9.
23. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-502.
24. Jacobs AD, Otero H, Picozzi VJ, Aboulafia DM. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest. 2004;22:505-14. (Pubitemid 39506870)
25. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
26. Pessaux P, Varma D, Arnaud J. Pancreaticoduodenectomy: superior mesenteric artery first approach. J Gastrointest Surg. 2006;10:607-11. (Pubitemid 43619154)
27. Weitz J, Rahbari N, Koch M, Büchler MW. The "artery first" approach for resection of pancreatic head cancer. J Am Coll Surg. 2010;210:e1-4.
28. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240:205-13. (Pubitemid 38963009)
29. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: An international study group (ISGPF) definition. Surgery. 2005;138:8-13. (Pubitemid 40933766)
30. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93:1232-7. (Pubitemid 44547022)
31. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A, eds. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
32. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188-96.
33. Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB. 2013. doi: 10.1111/hpb.12154.
34. Valsangkar NP, Bush DM, Michaelson JS, et al. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17:257-66.
35. Huebner M, Kendrick M, Reid-Lombardo KM, et al. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:920-6.
36. Konstantinidis IT, Warshaw AL, Allen JN, et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013;257:731-6.
37. Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011;254:311-9.
38. Delpero JR, Bachellier P, Regenet N, et al. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB. 2013;16:20-33.
39. Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15:1651-60.
40. Katz MHG, Pisters PWT, Evans DB, et al. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-46; discussion 846-8.
41. Leichtle SW, Kaoutzanis C, Mouawad NJ, et al. Classic Whipple versus pylorus-preserving pancreaticoduodenectomy in the ACS NSQIP. J Surg Res. 2013;183:170-6.
42. Schäfer M, Müllhaupt B, Clavien P-A. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg. 2002;236:137-48. (Pubitemid 34809532)
43. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364:2128-37.
44. Kneuertz P, Pitt H, Bilimoria K. Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg. 2012;16:1727-35.
45. Schmidt J, Abel U, Debus J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012;30:4077-83.